CC-122-ST-001 Part A

Subjects with a treatment emergent adverse event (AE) by preferred term(1)
Dose in mg 0.5 1.5 2.5 3.5 Overall Overall 
Subjects n=3 n=4 n=3 n=3 n=6 n=8 n=7 n=34 
AE          
Fatigue 17 50 
Neutropenia 10 29.4 
Asthenia 20.6 
Constipation 20.6 
Nausea 20.6 
Dyspnea 17.6 
Vomiting 17.6 
Anemia 14.7 
Decreased Appetite 14.7 
Diarrhea 14.7 
Dizziness 14.7 
Pruritis 14.7 
Pyrexia 14.7 
Alopecia 11.8 
Cough 11.8 
Headache 11.8 
Edema Peripheral 11.8 
Tumor Pain 11.8 
Urinary Tract Infection 11.8 
Subjects with a treatment emergent adverse event (AE) by preferred term(1)
Dose in mg 0.5 1.5 2.5 3.5 Overall Overall 
Subjects n=3 n=4 n=3 n=3 n=6 n=8 n=7 n=34 
AE          
Fatigue 17 50 
Neutropenia 10 29.4 
Asthenia 20.6 
Constipation 20.6 
Nausea 20.6 
Dyspnea 17.6 
Vomiting 17.6 
Anemia 14.7 
Decreased Appetite 14.7 
Diarrhea 14.7 
Dizziness 14.7 
Pruritis 14.7 
Pyrexia 14.7 
Alopecia 11.8 
Cough 11.8 
Headache 11.8 
Edema Peripheral 11.8 
Tumor Pain 11.8 
Urinary Tract Infection 11.8 

or Create an Account

Close Modal
Close Modal